# Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

Source: https://onco.cc/trials/nct02492711/  
OnCo record `nct02492711` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Margetuximab and Trastuzumab in Breast cancer, run by MacroGenics, completed.

## Summary

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer is a phase 3 interventional study registered as NCT02492711 by MacroGenics, with 624 participants recorded, started 2015-08-24 and reaching its primary completion in 2021-08-11. Interventions recorded: Margetuximab, Trastuzumab, Physician's choice of chemotherapy.. Conditions recorded: HER-2 Positive Breast Cancer, Metastatic Neoplasm.

Linked to the drug Margetuximab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02492711
- Phase: 3
- Setting: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
- Sponsor: MacroGenics
- Enrolled: 624

## Sources

- ClinicalTrials.gov NCT02492711: https://clinicaltrials.gov/study/NCT02492711

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Margetuximab](https://onco.cc/drugs/margetuximab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [MacroGenics](https://onco.cc/companies/macrogenics/)

---
JSON: https://onco.cc/api/v1/entities/nct02492711.json